Literature DB >> 24935260

JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort.

Gillian McGaffin1, Kirsteen Harper, David Stirling, Lorna McLintock.   

Abstract

Entities:  

Keywords:  Calreticulin; JAK2; calreticulin gene; exclusive; myeloproliferative

Mesh：

Substances：

Year:  2014        PMID： 24935260     DOI： 10.1111/bjh.12969

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  17 in total

1.  Next-generation deep-sequencing detects multiple clones of CALR mutations in patients with BCR-ABL1 negative MPN.

Authors:  S Jeromin; A Kohlmann; M Meggendorfer; S Schindela; K Perglerová; N Nadarajah; W Kern; C Haferlach; T Haferlach; S Schnittger
Journal:  Leukemia       Date:  2015-07-29       Impact factor: 11.528

Review 2.  Calreticulin (CALR) mutation in myeloproliferative neoplasms (MPNs).

Authors:  Wenyi Luo; Zhongxin Yu
Journal:  Stem Cell Investig       Date:  2015-08-31

Review 3.  Clinical relevance between CALR mutation and myeloproliferative neoplasms.

Authors:  Zhiyuan Wu; Chen Zhang; Xiaochao Ma; Ming Guan
Journal:  Stem Cell Investig       Date:  2015-02-16

4.  Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Authors:  Carla Al Assaf; Florence Van Obbergh; Johan Billiet; Els Lierman; Timothy Devos; Carlos Graux; Anne-Sophie Hervent; Jan Emmerechts; Thomas Tousseyn; Pascale De Paepe; Petros Papadopoulos; Lucienne Michaux; Peter Vandenberghe
Journal:  Haematologica       Date:  2015-05-01       Impact factor: 9.941

5.  p.Y317H is a new JAK2 gain-of-function mutation affecting the FERM domain in a myelofibrosis patient with CALR mutation.

Authors:  Laura Eder-Azanza; Cristina Hurtado; David Navarro-Herrera; Paula Aranaz; Francisco J Novo; José L Vizmanos
Journal:  Haematologica       Date:  2017-05-04       Impact factor: 9.941

6.  Coexisting JAK2V617F and CALR Exon 9 Mutation in Essential Thrombocythemia.

Authors:  Munazza Rashid; Rifat Zubair Ahmed; Shariq Ahmed; Muhammad Nadeem; Nuzhat Ahmed; Tahir Sultan Shamsi
Journal:  Indian J Hematol Blood Transfus       Date:  2016-02-09       Impact factor: 0.900

7.  A meta-analysis comparing clinical characteristics and outcomes in CALR-mutated and JAK2V617F essential thrombocythaemia.

Authors:  Yining Yang; Xiaorui Wang; Chun Wang; Youwen Qin
Journal:  Int J Hematol       Date:  2014-12-25       Impact factor: 2.490

8.  Somatic mutations of calreticulin in a Brazilian cohort of patients with myeloproliferative neoplasms.

Authors:  João Agostinho Machado-Neto; Paula de Melo Campos; Dulcinéia Martins de Albuquerque; Fernando Ferreira Costa; Irene Lorand-Metze; Sara Terezinha Olalla Saad; Fabiola Traina
Journal:  Rev Bras Hematol Hemoter       Date:  2015-04-15

9.  Calreticulin mutations in myeloproliferative neoplasms.

Authors:  Noa Lavi
Journal:  Rambam Maimonides Med J       Date:  2014-10-29

10.  Differential Dynamics of CALR Mutant Allele Burden in Myeloproliferative Neoplasms during Interferon Alfa Treatment.

Authors:  Lasse Kjær; Sabrina Cordua; Morten O Holmström; Mads Thomassen; Torben A Kruse; Niels Pallisgaard; Thomas S Larsen; Karin de Stricker; Vibe Skov; Hans C Hasselbalch
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.